Therapy and device convergence: The next generation
SESSION THEMES
Join keynote speaker Dr. Annemarie Moseley, CEO of Aggregate Therapeutics (Palo Alto) and moderator T. “Teo” Forcht Dagi, General Partner of HLM Venture Partners (Boston) for an interactive session exploring how drug-device combination products are altering the medical practice from development to regulation to treatment.The market for drug-device combinations worldwide was valued at $5.4 billion in 2004 and is expected to more than double to $11.5 billion by 2010. The proliferation of drug-device combination products is apparent in the 275 submitted to the FDA for approval in 2005. Examples include Canadian Angiotech Pharmaceuticals’ drug-eluting stent and Pfizer’s recently approved combination product Exubera, the first non-injectable insulin for the treatment of diabetes.
Session Designed For:
Capital providers and corporate managers involved in financing and developing novel technologies in health care.
Keynote Speaker:
Dr. Annemarie Moseley, CEO, Aggregate Therapeutics
Moderator:
T. "Teo" Forcht Dagi, General Partner, HLM Venture Partners (Boston, MA)
DATE | TIME | LOCATION
September 28, 20068:00AM - 9:30AM
MaRS Collaboration Centre, Ground Floor
101 College St., Toronto
DOWNLOADS AND RESOURCES
Emerging Technology Brief: "Combination Products: Biologic/Drug/Device Convergence" (PDF)Presentation:
ABOUT THE SPEAKER
Annemarie Moseley, PhD, MDCurrently Annemarie is the acting CEO of Aggregate Therapeutics, Inc, a commercialization effort of the Stem Cell Network of Canada. She is also Chairman of Repair Technologies, a biotech startup in the Bay Area focused on endogenous repair of tissue injury. Most recently she worked with Guidant as an internal clinical and regulatory fellow, focusing on initiatives in the biologics and device convergence areas. Before joining Guidant, Annemarie was the President and CEO at Cognate Therapeutics, a biotechnology company focused on multiple stem cell technologies, which she founded with Toucan Capital. Prior to founding Cognate, she was President and CEO of Osiris Therapeutics, and has held management roles at Titan Pharmaceuticals, Systemix and Applied Immune Sciences. Annemarie's experience includes pioneering clinical development of adult stem cell therapies, leading numerous biotech products through IND and IDE filing and managing product development from technology conception through Phase 3 clinical development in the US and Europe. She received her MD from Baylor College of Medicine, where she was specialized in Internal Medicine and completed fellowships in Genetics and Immunology. She received her PhD in Physiology and Biochemistry from Utah State University.
FOR MORE INFORMATION CONTACT
If you have any questions regarding this event, please contact Assunta KrehlEmail: akrehl@marsdd.com
Call: 416.673.8114
Or, click here for more information about the MaRS Emerging Technologies Event Series >>
PAST EVENTS
- March 18, 2008
MaRS Emerging Technologies Series - The Impact of Technology on Politics: The permanent campaign - May 28, 2007
Location! Location! Location! The Growing Market for Location-Based Services (LBS) - September 28, 2006
Therapy and device convergence: The next generation - February 27, 2006
Personalized Medecine: Genetic Diagnostics Technologies
